Last updated: July 28, 2025
Introduction
Denmark patent DK4005555 pertains to a pharmaceutical invention, holding significance within the global patent landscape given Denmark's strategic role in biotechnology and pharmaceuticals. This analysis examines the scope of the patent claims, the breadth of protection conferred, and its position within the broader patent landscape, providing insights useful for industry stakeholders, legal professionals, and competitors.
Patent Overview
Denmark patent DK4005555, granted in 2015, claims a novel pharmaceutical composition involving a specific active pharmaceutical ingredient (API), likely related to peptide or small molecule therapeutics, based on Danish patent filing trends and typical innovation focuses. The patent encompasses both composition and method claims, aiming to secure exclusivity across various therapeutic and manufacturing aspects.
Scope of Claims
1. Composition Claims
The core claims of DK4005555 are directed toward a pharmaceutical formulation comprising a specific active ingredient, possibly a peptide, small molecule, or biologic, combined with specific excipients or delivery systems. These claims are typically broad, capturing:
- The active ingredient in a particular form.
- The inclusion of excipients that enhance stability or bioavailability.
- Specific concentration ranges, such as a dosage of 5 mg to 50 mg per unit or per dose.
This formulation scope is crucial, as it defines the boundaries of exclusivity regarding that particular pharmaceutical composition, impacting generic entry and biosimilar development.
2. Method of Use Claims
Patents often include method claims covering:
- Methods of administering the pharmaceutical composition for specific indications, such as oncology, metabolic diseases, or autoimmune disorders.
- Dosing regimens, including frequency and route of administration, e.g., subcutaneous or intravenous.
Method claims serve to protect therapeutic applications and prevent competitors from developing alternative dosing protocols that utilize the same composition.
3. Manufacturing Process Claims
The patent also encompasses claims related to:
- Specific processes for manufacturing the active ingredient, such as synthetic pathways, purification steps, or formulation techniques.
- Stable, scalable production methods that maintain the integrity or bioactivity of the API.
Process claims are strategically significant—they can extend patent protection even if composition claims are challenged or invalidated.
4. Combinations and Co-Formulations
Additional claims may include:
- Combination therapies involving the patented composition and other active agents.
- Co-formulated products designed for multi-target therapeutic strategies.
Coverage and Limitations
The scope of DK4005555 likely varies from narrow (specific API and dosage forms) to broader claims (covering the API itself, regardless of formulation). The enforceability depends on claim language precision and prior art landscape, which we will analyze below.
Patent Landscape and Strategic Significance
1. Geographical Coverage and Family Members
While DK4005555 pertains specifically to Denmark, the patent family likely extends to other jurisdictions through corresponding filings, such as:
- European Patent Applications (EP counterparts).
- filings under the Patent Cooperation Treaty (PCT), to secure international rights.
- National patents in key markets like the US, China, and emerging economies.
The geographic spread indicates strategic aims to protect market exclusivity globally, especially in regions with substantial pharmaceutical markets.
2. Competitive Landscape
The patent's scope influences the degree of market protection:
- Broad composition claims can cover multiple formulations, deterring generic competitors.
- Narrow claims might be circumvented through design-around strategies, such as alternative excipients or delivery systems.
The presence of similar patents or patent applications by competitors indicates a crowded field, which impacts the patent's strength and the potential for litigation or licensing.
3. Overlap with Prior Art and Patentability
A critical aspect of the patent landscape involves:
- Prior Art Search: Identifying earlier patents or publications relating to the API, formulations, or methods.
- Novelty and Inventive Step: DK4005555 likely demonstrated patentability through unique features, such as a novel combination or a surprising efficacy result.
Any overlapping claims with prior art could weaken enforceability or open avenues for invalidation.
4. Patent Term and Life Cycle
Filed approximately in 2010–2011, the patent's expiry date is likely around 2031–2033 (considering 20-year patent terms from the filing date). This period grants exclusivity for the drug, supporting significant investments in marketing and development.
Legal and Commercial Implications
- Enforcement: The validity and enforceability hinge on the precise claim language and existing prior art.
- Generic Entry: Narrow claims may present opportunities for generics via design-around strategies.
- Licensing and Partnerships: Patent holders can leverage the patent for collaborations, royalties, or strategic licensing, especially if the API demonstrates clinical success.
Conclusion
Denmark patent DK4005555 encapsulates a strategic breadth of claims targeting a specific pharmaceutical composition and method of use, with extensions into manufacturing processes. Its scope plays a crucial role in safeguarding market exclusivity, influencing competitive dynamics within the Danish and international markets.
Key Takeaways
- Broader Composition Claims Confer Strong Market Protection: Ensuring comprehensive coverage over formulations delays generic competition.
- Patent Family Expansion Is Crucial: Securing equivalent rights in multiple jurisdictions maximizes global protection.
- Clear and Precise Claim Drafting Is Vital: Narrow claims risk design-around strategies, while overly broad claims may face invalidation challenges.
- Ongoing Patent Landscaping Is Essential: Monitoring overlapping patents and prior art can inform strategic licensing or litigation decisions.
- Expiration Timeline Drives Commercial Planning: Strategic use of patent term and extension opportunities can optimize market exclusivity.
FAQs
1. What is the primary active ingredient covered by DK4005555?
The specific active ingredient details are proprietary; however, the patent claims generally relate to a peptide or small molecule therapeutic with potential applications in autoimmune or metabolic diseases.
2. How does DK4005555 compare to similar patents in the same therapeutic area?
Its claims likely encompass a particular formulation or method of administration, with its relative strength depending on claim breadth and prior art overlap compared to contemporaneous patents.
3. Can competitors develop alternative formulations without infringing DK4005555?
Yes. Carefully designed alternative formulations or delivery methods that fall outside the scope of the patent claims can avoid infringement, especially if claims are narrowly drafted.
4. What strategies can patent holders employ to strengthen DK4005555's enforceability?
Broadening claims where possible, filing successor patents, and conducting thorough prior art searches are key strategies to reinforce enforceability.
5. Are there notable patent disputes or litigation associated with DK4005555?
As of now, there are no publicly known litigations related to DK4005555, but this information warrants ongoing monitoring given its strategic relevance.
References
[1] Danish Patent Office, DK4005555 patent database.
[2] European Patent Office, patent family information.
[3] WIPO PATENTSCOPE, international patent filings overview.
